Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

STAG2 expression in oral cancer and potentially malignant lesions

verfasst von: Vanessa Fátima Bernardes, Gefter Thiago Batista Correa, Adriano Mota Loyola, Sérgio Vitorino Cardoso, Alfredo Maurício Batista de Paula, Mônica Maria Demas Álvares Cabral, Ricardo Santiago Gomez, Carolina Cavaliéri Gomes

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Oral cancer is a world health problem, and one of the highest incidence rates of oral cancer worldwide occurs in Brazil. STAG2 is part of the cohesin complex which is responsible for sister chromatid cohesion. STAG2 loss of expression was reported in a range of tumors, and STAG2 loss was found to cause chromosomal instability and aneuploidy in cancer cells. On the basis of these findings, we investigated STAG2 expression in oral cancer and potentially malignant lesions. We investigated STAG2 immunoexpression in oral cancer, lip cancer, oral leukoplakia, and actinic cheilitis, including complete clinical information. Normal oral mucosa samples were included as normal controls. STAG2 protein was highly expressed in all samples. We further tested STAG2 expression in gastric adenocarcinomas and glioblastomas, as these tumor types were previously shown to lose STAG2 expression. We found homogenous expression of STAG2 by these tumor cells. Our results suggest that STAG2 loss of expression is not a common event in oral carcinogenesis.
Literatur
1.
Zurück zum Zitat de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP. Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck. 2010;32:357–67.PubMed de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP. Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck. 2010;32:357–67.PubMed
3.
4.
Zurück zum Zitat Mannini L, Menga S, Musio A. The expanding universe of cohesin functions: a new genome stability caretaker involved in human disease and cancer. Hum Mutat. 2010;31:623–30.PubMedCrossRef Mannini L, Menga S, Musio A. The expanding universe of cohesin functions: a new genome stability caretaker involved in human disease and cancer. Hum Mutat. 2010;31:623–30.PubMedCrossRef
5.
Zurück zum Zitat Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011;333:1039–43.PubMedCentralPubMedCrossRef Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011;333:1039–43.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Kim MS, Kim SS, Je EM, Yoo NJ, Lee SH. Mutational and expressional analyses of STAG2 gene in solid cancers. Neoplasma. 2012;59:524–9.PubMedCrossRef Kim MS, Kim SS, Je EM, Yoo NJ, Lee SH. Mutational and expressional analyses of STAG2 gene in solid cancers. Neoplasma. 2012;59:524–9.PubMedCrossRef
7.
Zurück zum Zitat Reshmi SC, Gollin SM. Chromosomal instability in oral cancer cells. J Dent Res. 2005;84:107–17.PubMedCrossRef Reshmi SC, Gollin SM. Chromosomal instability in oral cancer cells. J Dent Res. 2005;84:107–17.PubMedCrossRef
8.
Zurück zum Zitat Bernstein JM, Bernstein CR, West CM, Homer JJ. Molecular and cellular processes underlying the hallmarks of head and neck cancer. Eur Arch Otorhinolaryngol. 2013;270:2585–93.PubMedCrossRef Bernstein JM, Bernstein CR, West CM, Homer JJ. Molecular and cellular processes underlying the hallmarks of head and neck cancer. Eur Arch Otorhinolaryngol. 2013;270:2585–93.PubMedCrossRef
9.
Zurück zum Zitat American Joint Committee on Cancer. AJCC Cancer Staging Manual. New York: AJCC; 2002. American Joint Committee on Cancer. AJCC Cancer Staging Manual. New York: AJCC; 2002.
10.
Zurück zum Zitat Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. Lyon: IARC; 2005. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. Lyon: IARC; 2005.
11.
Zurück zum Zitat Walker RA. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49:406–10.PubMedCrossRef Walker RA. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49:406–10.PubMedCrossRef
12.
Zurück zum Zitat Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013;8:277–302.PubMedCrossRef Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013;8:277–302.PubMedCrossRef
13.
Zurück zum Zitat Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA, Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2010;18:433–41.PubMed Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA, Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2010;18:433–41.PubMed
Metadaten
Titel
STAG2 expression in oral cancer and potentially malignant lesions
verfasst von
Vanessa Fátima Bernardes
Gefter Thiago Batista Correa
Adriano Mota Loyola
Sérgio Vitorino Cardoso
Alfredo Maurício Batista de Paula
Mônica Maria Demas Álvares Cabral
Ricardo Santiago Gomez
Carolina Cavaliéri Gomes
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1482-8

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.